注射用替度格鲁肽新规格获批,低龄短肠综合征患儿迎新选择

新京报
Aug 07

新京报讯8月6日,武田中国宣布,旗下消化领域罕见病产品瑞唯抒(通用名:注射用替度格鲁肽)1.25mg规格正式获得国家药监局批准,相应扩展适应症用于治疗短肠综合征(Short bowel syndrome,简称SBS)校正胎龄4个月及以上儿童患者。此次1.25mg规格及扩展适应症的获批,使替度格鲁肽的适用年龄范围在此前成人和1岁及以上儿童患者的基础上进一步拓展至更低龄患儿。  短肠综合征是指因各种...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10